Although the most important prognostic and predictive marker in colorectal cancer is tumor cells in lymph nodes, ∼30% of patients who are node-negative die from occult metastases. Molecular staging employing specific markers and sensitive detection technologies has emerged as a powerful platform to assess prognosis in node-negative colon cancer. Integrating molecular staging into algorithms that individualize patient management will require validation and the definition of relationships between occult tumor cells, prognosis, and responses to chemotherapy. J. Surg. Oncol. 2012; 105:468-474. © 2012 Wiley Periodicals, Inc.
Copyright © 2012 Wiley Periodicals, Inc.
Recommended CitationMejia, Alex; Schulz, Stephanie; Hyslop, Terry; Weinberg, David S.; and Waldman, Scott A., "Molecular staging individualizing cancer management" (2012). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 34.